Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pharmacokinetic Study of Single Doses of ORM-12741 (Nebula PK 1)

5. mai 2015 oppdatert av: Orion Corporation, Orion Pharma

Pharmacokinetic Study of Modified Release Formulations and an Immediate Release Formulation of ORM-12741 After Single Oral Doses

The purpose of this study is to evaluate ORM-12741 concentrations in the blood after different study drug formulations

Studieoversikt

Detaljert beskrivelse

The purpose of this study is to evaluate the pharmacokinetics and safety of single doses of modified release formulations and a immediate release formulation of ORM-12741

Studietype

Intervensjonell

Registrering (Faktiske)

23

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Turku, Finland
        • Clinical Research Services Turku, CRST

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 65 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Written informed consent (IC) obtained.
  2. Good general health ascertained by detailed medical history and physical examination.
  3. Females and males between 18 and 65 years of age (inclusive).
  4. Body mass index (BMI) between 18-30 kg/m2 (inclusive, BMI = weight/height2).
  5. Weight of 50-100 kg (inclusive).
  6. Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or other intestinal problems).

Exclusion Criteria:

  1. Predicted poor compliance or inability to communicate well with the investigator or the study centre personnel.
  2. Veins unsuitable for repeated venipuncture or cannulation.
  3. Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease as judged by the investigator.
  4. Any condition requiring regular concomitant treatment (including vitamins and herbal products) or likely to need any concomitant treatment during the study. Hormonal contraception and hormone replacement therapy are allowed.
  5. Susceptibility to severe allergic reactions.
  6. Intake of any medication that could affect the outcome of the study, within 2 weeks prior to the first study treatment administration or less than 5 times the half-life of the medication. Possible enzyme inducing drugs will be discussed case-by-case with the sponsor.
  7. Regular consumption of more than 21 units of alcohol per week for males and 16 units per week for females (1 unit = 4 cl spirits, about 13 g of alcohol).
  8. Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.
  9. Inability to refrain from using nicotine-containing products during the stay at the study centre.
  10. Inability to refrain from consuming caffeine-containing beverages during the stay at the study centre, e.g. propensity to develop headaches when refraining from caffeine-containing beverages.
  11. Blood donation or loss of significant amount of blood within 3 months prior to the first study treatment administration.
  12. Any clinically significant 12-lead electrocardiogram (ECG) abnormality after a 10-minute rest in supine position at the screening visit, as judged by the investigator. For example:

    • QTc (calculated with the Bazett's formula) > 470 msec for females and 450 msec for men.
  13. HR < 45 beats/minute or > 100 beats/minute after a 10-minute rest in supine position at the screening visit.
  14. At the screening visit systolic blood pressure (BP) < 90 mmHg or > 150 mmHg after a 10- minute rest in supine position, diastolic BP < 50 mmHg or > 90 mmHg after a 10-minute rest in supine position, or symptomatic orthostatic hypotension, or

    • decrease of ≥ 20 mmHg of systolic BP or
    • decrease of ≥ 10 mmHg of diastolic BP after 3 minutes in standing position.
  15. Any abnormal value in laboratory tests, or vital signs, or physical examination finding, which in the opinion of the investigator could interfere with the interpretation of the test results or cause a health risk for the subject if he takes part in the study.
  16. History of drug abuse or positive result in drug abuse test.
  17. Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).
  18. Females of childbearing potential if they are not using proper contraception (hormonal contraception, intrauterine device [IUD] or surgical sterilization, spermicidal foam in conjunction with condom on male partner) during the study. Use of oral/hormonal contraception alone is not acceptable. (Note: women of childbearing potential with no current heterosexual relationship can be included without contraception according to the judgement of the investigator).
  19. Any other condition that in the opinion of the investigator would interfere with the evaluation of the results or constitute a health risk for the study subject.
  20. Participation in a clinical drug study within 3 months prior to the first study treatment administration of this study or earlier participation in a clinical study with ORM-12741.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Panel 1
Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
Formulering med modifisert utgivelse av ORM-12741
Formulering med modifisert utgivelse av ORM-12741
Immediate release formulation of ORM-12741
Eksperimentell: Panel 2
Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
Formulering med modifisert utgivelse av ORM-12741
Formulering med modifisert utgivelse av ORM-12741
Immediate release formulation of ORM-12741
Eksperimentell: Panel 3
Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
Formulering med modifisert utgivelse av ORM-12741
Formulering med modifisert utgivelse av ORM-12741
Immediate release formulation of ORM-12741
Eksperimentell: Panel 4
Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
Formulering med modifisert utgivelse av ORM-12741
Formulering med modifisert utgivelse av ORM-12741
Immediate release formulation of ORM-12741
Eksperimentell: Panel 5
Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
Formulering med modifisert utgivelse av ORM-12741
Formulering med modifisert utgivelse av ORM-12741
Immediate release formulation of ORM-12741
Eksperimentell: Panel 6
Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
Formulering med modifisert utgivelse av ORM-12741
Formulering med modifisert utgivelse av ORM-12741
Immediate release formulation of ORM-12741

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pharmacokinetics
Tidsramme: Blood samples collected frequently on day 1 and once or twice a day for 4 days
Explore the PK profile (e.g. Cmax, tmax, AUC, t1/2) and determine protein binding
Blood samples collected frequently on day 1 and once or twice a day for 4 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety measures, i.e. assessing adverse events, vital signs, ECG, safety laboratory values
Tidsramme: 24 hours per period
adverse events, vital signs, ECG, safety laboratory values
24 hours per period

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. september 2014

Primær fullføring (Faktiske)

1. februar 2015

Studiet fullført (Faktiske)

1. februar 2015

Datoer for studieregistrering

Først innsendt

6. oktober 2014

Først innsendt som oppfylte QC-kriteriene

17. desember 2014

Først lagt ut (Anslag)

18. desember 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

6. mai 2015

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. mai 2015

Sist bekreftet

1. mai 2015

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 3098011
  • 2014-000193-19 (EudraCT-nummer)

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere